110 likes | 169 Views
Schott, G; Pachl, H; Limbach, U; Gundert -Remy, U; Ludwig, W; Lieb, K
E N D
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279
Schott, G; Pachl, H; Limbach, U; Gundert-Remy, U; Ludwig, W; Lieb, K The Financingof Drug Trials byPharmaceutical Companies andItsConsequences: Part 1. A Qualitative, Systematic Review oftheLiterature on PossibleInfluences on theFindings, Protocols, and Quality of Drug Trials DtschArzteblInt 2010; 107(16): 279-85; DOI: 10.3238/arztebl.2010.0279